Physician profile
Antonio Mesa
NPI 1093717167
$5,576.32
in general payments reported to CMS, 2019-2025
25 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $306 · 2021: $615 · 2022: $595 · 2023: $1,205 · 2024: $1,927 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,370 · Travel and Lodging: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.76 |
| Travel and Lodging | $937.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,858.72 | 2021-2024 | Intracept |
| Stimwave Technologies Incorporated | $744.17 | 2019-2022 | |
| Relievant Medsystems, INC. | $687.38 | 2023 | Intracept |
| Nevro Corp. | $519.04 | 2022-2023 | Senza |
| Vertos Medical, INC. | $358.62 | 2022-2024 | Mild Device Kit |
| Biogen, INC. | $219.78 | 2021 | |
| Abbvie INC. | $179.27 | 2021-2025 | |
| Painteq LLC | $162.90 | 2024 | Painteq |
| Amgen INC. | $117.39 | 2019 | |
| Axonics, INC. | $94.96 | 2021 | |
| Allergan, INC. | $91.09 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $80.28 | 2020 | |
| Tg Therapeutics, INC. | $65.00 | 2025 | |
| Curonix LLC | $61.32 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Novartis Pharmaceuticals Corporation | $61.18 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $44.52 | 2019 | |
| Merz Pharmaceuticals, LLC | $39.35 | 2025 | Xeomin |
| Piramal Critical Care | $37.90 | 2021 | |
| Abbott Laboratories | $27.15 | 2025 | Eterna |
| Vertex Pharmaceuticals Incorporated | $27.03 | 2025 | |
| Livanova USA, INC. | $23.23 | 2019 | |
| Lilly USA, LLC | $20.72 | 2019 | |
| Nalu Medical, INC. | $18.72 | 2022 | |
| Neurocrine Biosciences, INC. | $18.55 | 2019 | |
| Electronic Waveform Lab, INC. | $18.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Mesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.